AUA 2026, BCG naive and BCG-Exposed High-Risk Non–muscle Invasive Bladder Cancer, Intravesical MK-3120, anti–Nectin-4 monoclonal antibody, MK-3120 I-VESIC.

Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...

Sara Khor presents a study linking pre-diagnosis financial hardship to late-stage cancer diagnosis, drawing on SEER, TransUnion credit report, and insurance claims data from appro ...

Overview on the use of androgen deprivation therapy (ADT) added to salvage radiation therapy (SRT) for prostate cancer patients with biochemical recurrence after prostatectomy. Th ...

Neeraj Agarwal discusses TALAPRO-3, a 599-patient phase 3 trial randomizing HRR-mutated metastatic hormone-sensitive prostate cancer patients to ADT plus enzalutamide plus talazoparib versus ADT plus ...

Metastatic prostate cancer is a leading cause of global cancer-related mortality. Contemporary treatment strategies are increasingly guided by genomic analyses, which are typically performed on ...

Erectile dysfunction (ED) is a common but often underdiagnosed and undertreated condition. It affects 20% to 57.8% of men, with prevalence increasing with age. Despite established guidelines, ...

Intravesical instillation therapy is the standard of care for patients with non-muscle-invasive bladder cancer (NMIBC) following transurethral resection (TURBT). Adherence to early and adjuvant ...

Current treatment of N1M0 prostate cancer (PCa) with locoregional external beam radiotherapy (EBRT) and long-term androgen deprivation therapy (ADT) has suboptimal five-year recurrence-free rates.

Pediatric neurogenic lower urinary tract dysfunction (NLUTD) is commonly managed with anticholinergic agents and clean intermittent catheterization (CIC). However, treatment options are limited for ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Anna Wilkins describes her validation of the Artera MMAI biomarker, drawing on over 2,000 biopsies from the 3,200-patient CHHiP radiotherapy fractionation trial in localized prostate cancer. The MMAI ...